Accurately target, detect, and treat Staphylococcus aureus (SA) infections with our cutting-edge diagnostic and therapeutic solution.
Introducing StaphMark: your frontline defense against Staphylococcus aureus (SA)infections. Powered by the 1D9 antibody, this advanced theranostic platform seamlessly merges diagnosis and treatment, delivering precision care exactly where it is needed. Whether used in live clinical settings or laboratory conditions, StaphMark changes the game in infection management.
The 1D9 antibody enables precise detection of infections, distinguishing between bacterial infection and sterile inflammation, leading to faster and more accurate clinical decisions.
Using radio theranostics and antimicrobial photodynamic therapy (aPDT), StaphMark could provide targeted infection treatment while minimizing damage to healthy tissues.
The platform shows potential in breaking down biofilms, allowing for more effective therapeutic interventions in complex infection environments.
By reducing reliance on broad-spectrum antibiotics, StaphMark helps mitigate the growing threat of AMR.
The 1D9 antibody is at the heart of StaphMark's theranostic power. Specifically designed to target Staphylococcus aureus (SA) bacteria, the 1D9 antibody binds to a unique surface protein found on SA. This precision targeting enables fast and accurate detection of SA infections, even when they are hidden within biofilms or deep in tissue.
At the core of the StaphMark platform is the 1D9 monoclonal antibody, a fully human antibody specifically designed for high-affinity binding to Staphylococcus aureus (including MRSA). This antibody exhibits substantial potential in both diagnostic and therapeutic applications, making it a versatile tool for managing bacterial infections.
Key features of the 1D9 antibody:
StaphMark’s theranostic technology provides real-time, actionable insights during both clinical diagnostics and surgical procedures, allowing healthcare professionals to detect and treat infections with unparalleled precision.
In Vivo Applications | Ex Vivo Applications |
---|---|
Surgical infection detection | Point-of-care diagnostics |
Real-time imaging in surgery | Nasal swab testing for SA |
Precise localization of infections | Synovial fluid analysis |
Unlike traditional methods that rely on broad-spectrum antibiotics, StaphMark precisely targets SA bacteria using imaging and therapeutic techniques. This reduces the risk of antibiotic resistance and minimizes damage to healthy tissues.
StaphMark uses real-time imaging, powered by 89Zirconium-labeled probes and fluorescent dyes, to localize and identify infections. This advanced diagnostic process allows for quicker, more accurate detection compared to conventional methods.
StaphMark is designed to treat Staphylococcus aureus (SA) infections, which are common in surgical sites, joint replacements, and fracture repairs. It’s particularly effective in tackling infections hidden within biofilms or deep in tissue.
StaphMark is currently undergoing clinical trials and regulatory approval processes in several regions.
By precisely targeting the infection site with radio theranostics and photodynamic therapy, StaphMark minimizes the need for broad-spectrum antibiotics, helping combat the rise of antibiotic resistance.
Yes, StaphMark’s real-time imaging capabilities make it an ideal tool for emergency surgeries where fast, accurate infection detection is critical. Its ability to guide therapeutic decisions on the spot helps surgeons respond effectively.
1D9 is a patented antibody that specifically binds to Staphylococcus aureus (SA) bacteria. It’s crucial for StaphMark’s theranostic process, as it enables the targeted detection and treatment of infections.
StaphMark offers continuous monitoring capabilities, allowing doctors to track infection treatment progress and ensure effective recovery. This reduces the chances of recurrence and helps guide post-surgical care decisions.